1 month ago
12
Novo Nordisk has launched its weight-loss drug Wegovy in China after it was approved by local health authorities in June.
According to BBC reports, it is set to intensify competition with rival Eli Lilly, whose popular weight-loss treatment also got the green light months ago but has yet to go on sale in the world’s second largest pharmaceutical market.
More than 1-hundred and 80 million people live with obesity in China, which has a population of 1-point-4 billion.
According to Chinese business news website Yicai, a dose of four Wegovy injections will cost 1,400 yuan or 1-hundred and 94-US dollars, a fraction of the drug’s price in the United States.
Yicai’s report says patients in China will have to pay the full price for the treatment, as the drug has not been included in the national healthcare insurance.
Research suggests that Wegovy patients can lose more than 10 percent of their body weight.
English (US) ·